AlphaLISA™ High Performance (HP) Human Interferon gamma (IFN-γ) Detection Kit

Product number: AL3153HV/C/F

Research Use Only. Not for use in diagnostic procedures.

# **Product Information**

**Application:** This kit is designed for the quantitative determination of human Interferon gamma using a homogeneous no wash AlphaLISA assay.

revvity

- **Kit contents:** The kit contains 5 components: AlphaLISA Acceptor beads coated with anti-human Interferon gamma Antibody, Streptavidin-coated Donor beads, Biotinylated anti-human Interferon gamma Antibody, Lyophilized human Interferon gamma analyte standard and 10X AlphaLISA HiBlock Buffer.
- Sensitivity: Lower Detection Limit (LDL): 0.34 pg/mL Lower Limit of Quantification (LLOQ): 1.31 pg/mL EC<sub>50</sub>: 5.81 ng/mL

**Dynamic Range:** 0.34 – 30 000 pg/mL




Figure 1. Typical sensitivity curve in AlphaLISA HiBlock Buffer. The data was generated using a gray AlphaPlate<sup>™</sup>-384 microplate and the EnVision<sup>®</sup> Multilabel Plate Reader 2102 with Alpha option.

#### Storage:

Store kit in the dark at 4 °C. For reconstituted analyte, aliquot and store at -20 °C. Avoid freeze-thaw cycles.

#### Stability:

This kit is stable for at least 24 months from the date of manufacture when stored in its original packaging and the recommended storage conditions.

### **Analyte of Interest**

Interferons (IFNs) activity has been discovered due to their antiviral effects. In humans, there are three families of IFNs: IFN type I (IFN- $\alpha$ ,  $\beta$ ,  $\omega$ ,  $\varepsilon$ , and  $\kappa$ ), IFN type II (one single representative, IFN- $\gamma$ ), and IFN type III (IFN- $\lambda$ 1-3). Antigens and mitogens stimulate in Natural Killer (NK) and activated helper T lymphocytes (Th1) the production of IFN- $\gamma$ . Human IFN- $\gamma$  is a 140 amino acids polypeptide that shows multiple effects; it induces the production of cytokines, upregulates the expression of class I and II MHC antigens, and leukocyte adhesion molecules. It also activates macrophages, enhances the secretion of immunoglobulins by B cells, and potentiates Th1 cell expansion. Response to IFN- $\gamma$  is mediated by the heterodimeric IFN- $\gamma$  Receptor, triggering a signalling cascade involving JAK1, JAK2, and STAT1. Importantly, IFNs have been proved to be effective in the treatment of several viral infections and cancers.

# **Description of the AlphaLISA Assay**

AlphaLISA technology allows the detection of molecules of interest in HiBlock buffer, RPMI, DMEM, or serum media in a highly sensitive, quantitative, reproducible and user-friendly mode. In this AlphaLISA assay, a biotinylated anti-human Interferon gamma antibody binds to the streptavidin coated AlphaLISA Donor beads, while the anti-human Interferon gamma antibody is conjugated to AlphaLISA Acceptor beads. In the presence of human Interferon gamma IFN- $\gamma$  analyte, the beads come into proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer within the Acceptor beads, resulting in emission with  $\lambda_{max}$  at 615 nm (Figure 2).




Figure 2. AlphaLISA HP human Interferon gamma (IFN-γ) Detection Assay Principle.

# Precautions

- The Alpha Donor beads are light-sensitive. All the other assay reagents can be used under normal light conditions. All Alpha assays using the Donor beads should be performed under subdued laboratory lighting (< 100 lux). Green filters (LEE 090 filters (preferred) or Roscolux filters #389 from Rosco) can be applied to light fixtures.</li>
- Take precautionary measures to avoid contamination of the reagent solutions.
- The biotinylated anti- human Interferon gamma antibody contains sodium azide. Contact with skin or inhalation should be avoided.

# **Kit Content: Reagents and Materials**

Kit components	AL3153HV 100 assay points***	AL3153C 500 assay points***	AL3153F 5000 assay points***
AlphaLISA Anti-human Interferon gamma (IFN-γ) Acceptor beads stored in PBS, 0.05% Kathon CG/ICP, pH 7.2	25 μL @ 5 mg/mL (1 brown tube, <u>white</u> cap)	50 µL @ 5 mg/mL (1 brown tube, <u>white</u> cap)	500 μL @ 5 mg/mL (1 brown tube, <u>white</u> cap)
Streptavidin (SA)-coated Donor beads stored in 25 mM HEPES, 100 mM NaCl, 0.05% Kathon CG/ICP, pH 7.4	100 μL @ 5 mg/mL (1 brown tube, <u>black</u> cap)	200 µL @ 5 mg/mL (1 brown tube, <u>black</u> cap)	2 x 1 mL @ 5 mg/mL (1 brown tube, <u>black</u> cap)
Biotinylated Anti-human Interferon gamma (IFN-γ) Antibody stored in PBS, 0.1% Tween-20, 0.05% NaN <sub>3</sub> , pH 7.4	25 µL @ 500 nM (1 tube, <u>black</u> cap)	50 µL @ 500 nM (1 tube, <u>black</u> cap)	500 μL @ 500 nM (1 tube, <u>black</u> cap)
Lyophilized human Interferon gamma (IFN-γ) Analyte*	0.1 μg (1 tube, <u>clear</u> cap)	0.1 μg (1 tube, <u>clear</u> cap)	0.1 μg (1 tube, <u>clear</u> cap)
AlphaLISA HiBlock Buffer (10X) **	2 mL, 1 small bottle	10 mL, 1 small bottle	100 mL, 1 large bottle

- \* Reconstitute lyophilized analyte in 100 µL Milli-Q<sup>®</sup> grade H<sub>2</sub>O. The reconstituted analyte should be used within 60 minutes or aliquoted into screw-capped 0.5 mL polypropylene vials and stored at - 20°C for future experiments. The aliquoted analyte at - 20°C is stable up to 28 days. Avoid freeze-thaw cycles. One vial contains an amount of analyte sufficient for performing 10 standard curves. Additional vials can be ordered separately (cat # AL3153S).
- \*\* Extra buffer can be ordered separately (cat # AL004C: 10 mL, cat # AL004F: 100 mL).
- \*\*\* The number of assay points is based on an assay volume of 100 μL in 96-well plates or 50 μL in 384-well assay plates using the kit components at the recommended concentrations.

Sodium azide should **not** be added to the stock reagents. High concentrations of sodium azide (> 0.001% final in the assay) might decrease the AlphaLISA signal. Note that sodium azide from the biotinylated anti-Anti-human Interferon gamma (IFN- $\gamma$ ) antibody stock solution will not interfere with the AlphaLISA signal (0.0001% final in the assay).

#### Specific additional required reagents and materials:

The following materials are recommended:

ltem	Suggested source	Catalog #
TopSeal™-A Plus Adhesive Sealing Film	Revvity Inc.	6050185
EnVision®-Alpha Reader	Revvity Inc.	-

# Recommendations

#### IMPORTANT: PLEASE READ THE RECOMMENDATIONS BELOW BEFORE USE

- The volume indicated on each tube is guaranteed for single pipetting. Multiple pipetting of the reagents may reduce the theoretical amount left in the tube. To minimize loss when pipetting beads, it is preferable not to pre-wet the tip.
- Centrifuge all tubes (including lyophilized analyte) before use to improve recovery of content (2000*g*, 10-15 sec). Re-suspend all reagents by vortexing before use.
- Use Milli-Q<sup>®</sup> grade H<sub>2</sub>O to dilute 10X AlphaLISA HiBlock Buffer and to reconstitute the lyophilized analyte.
- When diluting the standard or samples, <u>change tips</u> between each standard or sample dilution. When loading
  reagents in the assay microplate, <u>change tips</u> between each standard or sample addition and after each set
  of reagents.
- When reagents are added to the microplate, make sure the liquids are at the bottom of the well.
- Small volumes may be prone to evaporation. It is recommended to cover microplates with TopSeal-A Adhesive Sealing Films to reduce evaporation during incubation. Microplates can be read with the TopSeal-A Film in place.
- The AlphaLISA signal is detected with an EnVision Multilabel Plate Reader equipped with the Alpha option using the AlphaScreen standard settings (e.g. Total Measurement Time: 550 ms, Laser 680 nm Excitation Time: 180 ms, Mirror: D640as, Emission Filter: M570w, Center Wavelength 570 nm, Bandwidth 100 nm, Transmittance 75%).
- AlphaLISA signal will vary with temperature and incubation time. For consistent results, identical incubation times and temperature should be used for each plate.
- The standard curves shown in this technical data sheet are provided for information only. A standard curve must be generated for each experiment.

### Assay Procedure

- The protocol described below is an example for generating one standard curve in a 50 µL final assay volume (48 wells, triplicate determinations). The protocols also include testing samples in 452 wells. If different amount of samples are tested, <u>the volumes of all reagents have to be adjusted accordingly</u>, as shown in the table <u>below</u>. These calculations do not include excess reagent to account for losses during transfer of solutions or dead volumes.
- The standard dilution protocol is provided for information only. As needed, the number of replicates or the range of concentrations covered can be modified.
- Use of four background points in triplicate (12 wells) is recommended when LDL/LLOQ is calculated. One background point in triplicate (3 wells) can be used when LDL/LLOQ is not calculated.

			Volume			
Format	# of data points	Final	Sample	MIX AlphaLISA AccBeads + biotinylated Ab	SA-Donor beads	Plate recommendation
AL3153HV	100	100 µL	10 µL	40 µL	50 µL	White OptiPlate-96 (cat # 6005290) White ½ AreaPlate-96 (cat # 6005560)
	250	100 µL	10 µL	40 µL	50 µL	White OptiPlate-96 (cat # 6005290)
41 24520	500	50 µL	5 µL	20 µL	25 µL	1⁄2 Area AlphaPlate-96 (cat # 6002350) White OptiPlate-384 (cat # 6007290) Light gray AlphaPlate ™- 384 (cat # 6005350)
AL3153C	1 250	20 µL	2 µL	8 µL	10 µL	Light gray AlphaPlate-384 (cat # 6005350) ProxiPlate™-384 Plus (cat # 6008280) White OptiPlate-384 (cat # 6007290)
	2 500	10 µL	1 µL	4 µL	5 µL	Light gray AlphaPlate- 1536 (cat # 6004350)
	5 000	50 µL	5 µL	20 µL	25 µL	1 ∕₂ Area AlphaPlate-96 (cat # 6002350) White OptiPlate-384 (cat # 6007290) Light gray AlphaPlate-384 (cat # 6005350)
AL3153F	12 500	20 µL	2 µL	8 µL	10 µL	Light gray AlphaPlate-384 (cat # 6005350) ProxiPlate-384 Plus (cat # 6008280) White OptiPlate-384 (cat # 6007290)
	25 000	10 µL	1 µL	4 µL	5 µL	Light gray AlphaPlate- 1536 (cat # 6004350)


The 2-Step protocol described below is for 500 assay points including one standard curve (48 wells) and samples (452 wells). If different amount of samples are tested, the volumes of all reagents have to be adjusted accordingly.

- 1) <u>Preparation of 1X AlphaLISA HiBlock Buffer</u>: Add 5 mL of 10X AlphaLISA HiBlock Buffer to 45 mL Milli-Q<sup>®</sup> grade H<sub>2</sub>O.
- 2) <u>Preparation of human Interferon gamma (IFN-γ) analyte standard dilutions</u>:
  - a. Reconstitute lyophilized human IFN-γ (0.1μg) in 100 μL Milli-Q<sup>®</sup> grade H<sub>2</sub>O. The remaining reconstituted analyte should be aliquoted immediately and stored at -20 °C for future assays (see page 3 for more details).
  - b. A standard curve must be generated for each experiment. The standard curve should be performed in a similar matrix diluent as the samples (e.g. cell culture media for cell supernatant samples, FBS for serum samples). Use of the 1X AlphaLISA HiBlock Buffer is recommended as a diluent to confirm assay performance.
  - c. Prepare standard dilutions as follows in 1X AlphaLISA HiBlock Buffer (change tip between each standard dilution):

Vol. of			[Human IFN-γ] in standard curve		
	Human IFN-γ (μL)	diluent (µL) *	(g/mL in 5 μL)	(pg/mL in 5 µL)	
A	10 μL of reconstituted hIFN-γ	90	1.00E-07	100 000	
В	60 µL of tube A	140	3.00E-08	30 000	
С	60 µL of tube B	120	1.00E-08	10 000	
D	60 µL of tube C	140	3.00E-09	3 000	
E	60 µL of tube D	120	1.00E-09	1 000	
F	60 µL of tube E	140	3.00E-10	300	
G	60 μL of tube F	120	1.00E-10	100	
Н	60 µL of tube G	140	3.00E-11	30	
I	60 µL of tube H	120	1.00E-11	10	
J	60 μL of tube I	140	3.00E-12	3	
K	60 μL of tube J	120	1.00E-12	1.0	
L	60 µL of tube K	140	3.00E-13	0.3	
M ** (background)	0	100	0	0	
N ** (background)	0	100	0	0	
O ** (background)	0	100	0	0	
P ** (background)	0	100	0	0	

- \* Dilute standards in diluent (e.g. 1X AlphaLISA HiBlock Buffer). At low concentrations of analyte, a significant amount of analyte can bind to the vial. Therefore, load the analyte standard dilutions in the assay microplate within 60 minutes of preparation.
- \*\* Four background points in triplicate (12 wells) are used when LDL is calculated. If LDL does not need to be calculated, one background point in triplicate can be used (3 wells).
- Preparation of 2.5X MIX AlphaLISA Anti-human IFN-γ Acceptor beads (25 µg/mL) + Biotinylated Anti-human IFN-γ Antibody (2.5 nM):
  - a. Prepare just before use.
  - b. Add 50 μL of 5 mg/mL AlphaLISA Anti-human IFN-γ Acceptor Bead and 50 μL of 500 nM Biotinylated Anti-human IFN-γ Antibody to 9 900 μL of 1X AlphaLISA HiBlock Buffer.
- 4) Preparation of 2X Streptavidin (SA) Donor beads (80 µg/mL):
  - a. Prepare just before use.

- b. Keep the beads under subdued laboratory lighting.
- c. Add 200 µL of 5 mg/mL SA-Donor beads to 12 300 µL of 1X AlphaLISA HiBlock Buffer.
- 5) In a Gray AlphaPlate (384 wells):



# Data Analysis

- Calculate the average count value for the background wells.
- Generate a standard curve by plotting the AlphaLISA counts versus the concentration of analyte. A log scale can be used for either or both axes. No additional data transformation is required.
- Analyze data according to a nonlinear regression using the 4-parameter logistic equation (sigmoidal dose-response curve with variable slope) and a 1/Y<sup>2</sup> data weighting (the values at maximal concentrations of analyte after the hook point should be removed for correct analysis).
- The LDL is calculated by interpolating the average background counts (12 wells without analyte) + 3 x standard deviation value (average background counts + (3xSD)) on the standard curve.
- The LLOQ as measured here is calculated by interpolating the average background counts (12 wells without analyte) + 10 x standard deviation value (average background counts + (10xSD)) on the standard curve. Alternatively, the true LLOQ can be determined by spiking known concentrations of analyte in the matrix and measuring the percent recovery, and then determining the minimal amount of spiked analyte that can be quantified within a given limit (usually +/- 20% or 30% of the real concentration).
- Read from the standard curve the concentration of analyte contained in the samples.
- If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

# **Assay Performance Characteristics**

AlphaLISA assay performance described below was determined using the 2-step standard protocol and AlphaLISA HiBlock buffer as assay buffer. The analytes (standards) were prepared in AlphaLISA HiBlock Buffer, RPMI +10% FBS, DMEM + 10% FBS or 100% FBS serum. All other components were prepared in HiBlock buffer.

#### • Assay Sensitivity:

The LDL was calculated as described above. The values correspond to the lowest concentration of analyte that can be detected in a volume of 5  $\mu$ L sample using the recommended assay conditions.

LDL (pg/mL)	(Analyte diluent)	# of experiments
0.37	HiBlock buffer	41
0.54	RPMI + 10% FBS	5
0.85	DMEM + 10% FBS	5
0.34	100% FBS	3

#### <u>Assay Precision:</u>

The following assay precision data were calculated from the three independent assays using two different kit lots. In each lot, the analytes were prepared in HiBlock buffer or RPMI +10% FBS, DMEM + 10% FBS or 100% human serum. All other components were prepared in HiBlock buffer. Each assay consisted of one standard curve comprising 12 data points (each in triplicate) and 12 background wells (no analytes). The assays were performed in 384-well plate format.

#### o <u>Intra-assay precision:</u>

The intra-assay precision was determined using a total of 3 independent determinations in triplicate with 3 measurements for 700 pg/mL sample. Shown as CV%.

hIFN-γ	HiBlock buffer	RPMI +10% FBS	DMEM +10% FBS	Human Serum
Intra-CV (%)	1%	1%	3%	3%

#### • Inter-assay precision:

The inter-assay precision was determined using a total of 3 independent determinations with 9 measurements for 700 ng/mL sample. Shown as CV%.

hIFN-γ	HiBlock buffer	RPMI +10% FBS	DMEM +10% FBS	Human Serum
Inter-CV (%)	5%	5%	3%	2%

### Spike Recovery:

Two known concentrations of analyte were spiked into HiBlock buffer or RPMI +10% FBS, DMEM + 10% FBS or 100% human serum. All samples, including non-spiked diluents were measured in the assay. Note that the analytes for the respective standard curves were prepared in HiBlock buffer or RPMI +10% FBS, DMEM + 10% FBS or human serum. All other assay components were diluted in HiBlock buffer.

% Recovery
------------

Spiked <b>hIFN-γ</b> (pg/mL)	HiBlock buffer	RPMI +10% FBS	DMEM +10% FBS	Human Serum
700	99%	106%	106%	95%
350	99%	109%	110%	99%

### • Specificity:

Cross-reactivity of the AlphaLISA human Interferon gamma IFN- $\gamma$  HP Detection Kit was tested using the following proteins from 100 ng/mL to 0.3 pg/mL in HiBlock buffer. The cross reactivities were calculated using the signals of 100 ng/mL human IFN- $\gamma$  as 100%. No unwanted cross-reactions with related human Interferon gamma IFN- $\gamma$  protein were observed.

Proteins	Cross Reactivity (%)
Mouse IFN-γ	0%
Rat IFN-γ	0%
Canine IFN-γ	0%
Macaque IFN-γ	5%

### <u>Calibration</u>

Human IFN-γ NIBSC/WHO First International Standards (code 82/587 and 87/586) was tested using the AlphaLISA HP Human IFN-γ detection kit: 1 unit of Standard NIBSC 82/587 & 87/586 corresponds to 59.1 pg/mL & 88.2 pg/mL of AlphaLISA hIFN-γ respectively.

### **Troubleshooting Guide**

You will find detailed recommendations for common situations you might encounter with your AlphaLISA Assay kit at: <u>http://www.revvity.com</u>

### FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.



The information provided in this document is for reference purposes only and may not be all-inclusive. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume liability for the accuracy or completeness of the information contained herein. Users should exercise caution when handling materials as they may present unknown hazards. Revvity shall not be liable for any damages or losses resulting from handling or contact with the product, as Revvity cannot control actual methods, volumes, or conditions of use. Users are responsible for ensuring the product's suitability for their specific application. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF

www.revvity.com



For a complete listing of our global offices, visit www.revvity.com Copyright ©2023, Revvity, Inc. All rights reserved.